Surender Singh, MD
Family Medicine · Hanover, MANPI 1063574457
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 526 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 34 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $2,765 and has fallen 99.1% since, to $24 in 2025. Among family medicine clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 526 payments — averaging $23.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- AstraZeneca$2K
- Teva Pharmaceuticals USA, Inc.$965
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$786
- GSK$729
- Otsuka America Pharmaceutical, Inc.$673
- plus $4K from 28 others
What the payments were for
- Food & beverage$12,470100%
- Education$620%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 133 | $2,638 |
| AstraZeneca | 89 | $2,453 |
| Teva Pharmaceuticals USA, Inc. | 41 | $965 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 38 | $786 |
| GSK | 23 | $729 |
| Otsuka America Pharmaceutical, Inc. | 26 | $673 |
| Sunovion Pharmaceuticals Inc. | 14 | $521 |
| Boehringer Ingelheim | 16 | $485 |
| Takeda Pharmaceuticals U.S.A., Inc. | 23 | $462 |
| Alkermes, Inc. | 18 | $402 |
| Merck | 16 | $287 |
| Novo Nordisk | 14 | $260 |
| Pfizer | 14 | $258 |
| Johnson & Johnson | 6 | $229 |
| Nestle Healthcare Nutrition Inc. | 3 | $222 |
| Lundbeck LLC | 10 | $202 |
| UCB, Inc. | 1 | $134 |
| Eisai Inc. | 6 | $122 |
| Novartis | 6 | $121 |
| Kowa Pharmaceuticals America, Inc. | 6 | $121 |
| Idorsia Pharmaceuticals US Inc | 5 | $96 |
| Bausch Health US, LLC | 4 | $73 |
| Lilly USA, LLC | 2 | $37 |
| Esperion Therapeutics, Inc. | 2 | $34 |
| E.r. Squibb & Sons, L.L.C. | 1 | $32 |
| Hologic Sales And Service, LLC | 1 | $29 |
| Sage Therapeutics, LLC | 1 | $26 |
| Madrigal Pharmaceuticals | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $21 |
| Exact Sciences | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $19 |
| Acerus Pharmaceuticals Corporation | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Organogenesis Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,532 in reported general payments places this provider in the 95th percentile of 1,049 family medicine providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Duloxetine Hcl | 33 | $824 |
| Quetiapine Fumarate | 51 | $782 |
| RivastigmineRivastigmine Tartrate | 14 | $600 |
| Ziprasidone Hcl | 11 | $575 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 13 | $473 |
| Atorvastatin Calcium | 42 | $471 |
| Omeprazole | 17 | $326 |
| Metoprolol Succinate | 25 | $297 |
| Enalapril Maleate | 21 | $190 |
| Amlodipine Besylate | 17 | $168 |
| Doxazosin Mesylate | 16 | $152 |
| Trazodone Hcl | 27 | $118 |
| Pantoprazole Sodium | 14 | $111 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 11 | $107 |
| Pravastatin Sodium | 11 | $93 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Hanover
- Larry CulpepperBoston$109K
- Jennifer WeylerWorcester$105K
- Megan McCoyFramingham$75K
- Kristina GraceyWorcester$73K
- Suzanne MitchellBoston$69K
- John GrievesonLowell$24K
- James SalemisRoslindale$24K
- David FarzanLawrence$23K
- Julie JohnstonLawrence$21K
- Sanjeev SharmaFramingham$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.